To evaluate the efficacy of ivosidenib with venetoclax-based regimens, 31 patients with IDH1-mutated AML were studied in a phase 1b trial of ivosidenib and venetoclax with or without azacytidine [71]. The gene discussed is IDH1; the disease is acute myeloid leukemia.